ArticleJournal of cachexia, sarcopenia and muscle2012
Research on cachexia, sarcopenia and skeletal muscle in cardiology.
Article in Journal of cachexia, sarcopenia and muscle, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- An aetiology-based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) trial.ESC heart failure · 2021Trial
- Extracellular Vesicles in the Heart-Organ Axis: From Inter-Organ Communication to Precision Nanomedicine for Heart Diseases.International journal of nanomedicine · 2026Review
- Exosome‑mediated crosstalk between the cardiovascular and musculoskeletal systems: Mechanisms and therapeutic potential (Review).International journal of molecular medicine · 2025Review
- Sarcopenia-derived exosomal micro-RNA 16-5p disturbs cardio-repair via a pro-apoptotic mechanism in myocardial infarction in mice.Scientific reports · 2021Article
- Review
- Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia.Annals of geriatric medicine and research · 2019Review
- The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.Journal of cachexia, sarcopenia and muscle · 2017Article
- Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia.Scientific reports · 2017Article
- Muscle wasting in heart failure : The role of nutrition.Wiener klinische Wochenschrift · 2016Review
- Cardiac cachexia: hic et nunc.Journal of cachexia, sarcopenia and muscle · 2016Review
- Improved Ventilatory Efficiency with Locomotor Muscle Afferent Inhibition is Strongly Associated with Leg Composition in Heart Failure.International journal of cardiology · 2016Article
- Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment.Journal of cachexia, sarcopenia and muscle · 2015Review
- Muscle wasting in ageing and chronic illness.ESC heart failure · 2015Review
- Febuxostat improves outcome in a rat model of cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2015Article
- From sarcopenia to frailty: a road less traveled.Journal of cachexia, sarcopenia and muscle · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe awareness of cardiac cachexia, i.e. involuntary weight loss in patients with underlying cardiovascular disease, has increased over the last two decades. METHODS AND
resultsThis mini-review looks at recent research in the cardiovascular literature that is relevant to the areas of interest of the Journal of Cachexia, Sarcopenia and Muscle. It identifies significant research in the last 3 years on the obesity paradox, the causes and effects of skeletal muscle wasting, animal models of cachexia and emerging treatment ideas in cardiac cachexia.
conclusionsAssuming a similar literature in the fields of cancer, chronic obstructive pulmonary disease, chronic renal failure and chronic liver failure, the emergence of cachexia as a vibrant area of clinical and experimental research seems assured.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.